Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit dips below year-ago levels
Q1 FY2026 gross profit of $106M fell 4.2% year over year, behind the +11.3% change in trailing-twelve-month gross profit. Sequentially, it fell 40.4% from the prior quarter. Over 3 fiscal years it compounded at +19.0% a year.
Context
- Gross profit amounted to 83.8% of revenue in FY2025, down 2.5 pp from a year earlier.
- Gross profit increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -4.2% toward the trailing-twelve-month pace of +11.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 564M USD
- Year-over-year change
- +16.6%
- 4-year CAGR
- +13.9%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 564M | +16.6% |
| FY2024 | 2024-12-31 | 483.5M | +24.3% |
| FY2023 | 2023-12-31 | 389.04M | +16.1% |
| FY2022 | 2022-12-31 | 335.01M | -0.1% |
| FY2021 | 2021-12-31 | 335.4M | — |
Gross Profit vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's LTM Mar 2026 gross profit of $559.44M is the 4th highest of the 11 companies compared; the peer median is $10.48M.
- Its year-over-year change of +11.3% is the 8th highest of 11, against a peer median of +70.8%.
- Gross profit amounts to 83.6% of revenue for RARE, versus a peer median of 79.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $821.17B | +32536.1% | +16.0% | 79.9% | |
| LTM Jun 2026 | $828.57M | -51.6% | +36.4% | 82.1% | |
| LTM Jun 2026 | $665.62M | +193.4% | +85.5% | 93.3% | |
| LTM Mar 2026 | $559.44M | +11.3% | +19.0% | 83.6% | |
| LTM Mar 2026 | $73.09M | +682.6% | +68.8% | 91.6% | |
| LTM Mar 2026 | $13.42M | +23.0% | -48.1% | 74.1% | |
| LTM Mar 2026 | $7.55M | +1072.9% | +64.5% | 51.9% | |
| LTM Mar 2026 | -$120K | -100.1% | +37.2% | 0.1% | |
| LTM Mar 2026 | -$528.63K | +51.3% | +12.5% | 105.7% | |
| LTM Mar 2026 | -$2.15M | +8.3% | — | — | |
| LTM Mar 2026 | -$10.98M | +90.3% | — | 12.4% | |
| Peer median (excluding RARE) | $10.48M | +70.8% | +36.8% | 79.9% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 351.41M | 363.33M | 434.25M | 560.23M | 673M |
| Cost of Revenue | 16.01M | 28.32M | 45.21M | 76.73M | 109M |
| Gross Profit | 335.4M | 335.01M | 389.04M | 483.5M | 564M |
| Gross Margin | 95.4% | 92.2% | 89.6% | 86.3% | 83.8% |
| Research & Development | 497.15M | 705.79M | 648.45M | 697.87M | 750M |
| Selling, General & Admin | 219.98M | 278.14M | 309.8M | 321.61M | 349M |
| Operating Expenses | 717.14M | 983.93M | 958.25M | 1.02B | 1.1B |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| EBITDA | (410.32M) | (640.49M) | (516.45M) | (469M) | (474M) |
| EBITDA Margin | -116.8% | -176.3% | -118.9% | -83.7% | -70.4% |
| Operating Income | (381.74M) | (648.92M) | (569.21M) | (535.97M) | (535M) |
| Operating Margin | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| Interest Income | 1.93M | 11.07M | 26.69M | 36.51M | 25M |
| Interest Expense | 29.42M | 43.02M | 66M | 63.04M | 62M |
| Other Income / Expenses | (71.24M) | (52.81M) | (39.26M) | (31.61M) | (36M) |
| Income Before Tax | (452.98M) | (701.73M) | (608.46M) | (567.59M) | (571M) |
| Pre-Tax Margin | -128.9% | -193.1% | -140.1% | -101.3% | -84.8% |
| Income Tax Expense | 1.04M | 5.7M | (1.83M) | 1.6M | 4M |
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Net Margin | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% |
| EPS (Basic) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| EPS (Diluted) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| Weighted Avg Shares | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
| Weighted Avg Shares (Diluted) | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.